$CRDF I think we will continue to see slam-dunk data from all the future trials: "We have significant experience and expertise with biomarkers and technology in cancer, including CRC and AML. We are using our Precision Cancer MedicineTM (“PCMTM”) technology to measure PLK1 enzymatic activity to potentially identify patients most likely to respond to onvansertib and to measure patient therapy response". They have proven it in CRC data with 91% efficacy. This is totally unheard of from a deadly cancer!
  • 3
3 Likes